Novo Nordisk plans to put its clinical-study data alongside evidence from routine health care to examine obesity, diabetes and cardiovascular disease, including treatment outcomes beyond weight loss.
nference announced the collaboration Nov. 18. Medical records, diagnostic information and other real-world sources are expected to supplement Novo’s clinical-study material. nference said its AI platform and federated health-data network would support the research, with privacy and governance safeguards.
The planned work includes assessing treatment performance and safety, disease progression and longer-term health outcomes. nference also named research on clinical pharmacology and combined therapies, as well as more tailored trials that measure overall health alongside changes in weight.
Jacob Sten Petersen, Novo’s group vice president for R&D external innovation, said, “We see a significant opportunity to use AI and data.”
nference said the partners also plan to explore health-focused ventures using data and AI. Its announcement did not provide a timetable, name studies or medicines, or specify funding or commercial terms for those ventures.



